Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial
Posted inGastroenterology news Pediatrics

Mirikizumab Shows Promising Efficacy and Acceptable Safety in Pediatric Moderately-to-Severely Active Ulcerative Colitis: Results from the SHINE-1 Phase 2 Trial

The multicentre open-label SHINE-1 phase 2 trial found that mirikizumab produced clinically meaningful induction and maintenance responses in children with moderate-to-severe ulcerative colitis, with an acceptable safety profile over 52 weeks, supporting further randomized evaluation.
Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs
Posted inDermatology news

Oral Icotrokinra Achieves Rapid Skin Clearance in Moderate‑to‑Severe Plaque Psoriasis: Phase 3 Data from ICONIC and ADVANCE Programs

Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and fewer adverse events than deucravacitinib through 24 weeks.